Quantum BioPharma Ltd Dossier - Source-backed chat

Quantum BioPharma Ltd

QNTMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.64

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.42Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $22M

Enterprise Value $21.4M

Shares Outstanding 6.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Quantum BioPharma Ltd. (formerly FSD Pharma Inc.) is transitioning from a speculative early-stage biotech into a more disciplined operator, significantly reducing its operating cash burn by 60% year-over-year in Q1 2026 and extending its runway to July 2027. However, the investment thesis is currently balanced by a high-profile FDA clinical hold on its lead drug candidate, Lucid-MS, which has delayed the initiation of its Phase 2 clinical trial. While the company possesses a unique non-dilutive funding mechanism via a 7% royalty on the commercialization of the 'unbuzzd' hangover remedy and a potential $700 million market manipulation lawsuit, the near-term clinical delays and high stock volatility warrant a cautious Hold stance until regulatory clarity is achieved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.57

Mean target$12.57

High · most bullish analyst$12.57

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

The FDA clinical hold on Lucid-MS is prolonged due to complex safety or manufacturing questions, requiring expensive new preclinical studies that deplete Quantum's cash reserves. Meanwhile, Unbuzzd's commercial rollout struggles to gain traction in a highly competitive functional beverage market, failing to generate meaningful royalties. The company is forced to raise dilutive capital or issue more convertible debentures, further depressing the stock price.

Base CaseCentral scenario

$5.5055%

Quantum BioPharma works collaboratively with the FDA to resolve the clinical hold on Lucid-MS, pushing the Phase 2 trial initiation into late 2026 or early 2027. The company maintains its disciplined cost structure, keeping its cash burn low and preserving its $9.8 million treasury runway. Unbuzzd Wellness begins its regional rollout in Florida and Texas, but material royalty revenues take time to scale, keeping the company reliant on its existing capital reserves.

Bull CaseUpside scenario

$12.0025%

The FDA clinical hold on Lucid-MS is lifted swiftly in late 2026, allowing the Phase 2 trial to proceed with Allucent. Concurrently, Unbuzzd Wellness Inc. successfully executes its nationwide rollout of the clinically validated unbuzzd™ beverage under CEO Richard Buzbuzian, generating rapid sales and triggering substantial 7% royalty payments to Quantum. Additionally, positive momentum in the $700 million market manipulation lawsuit against CIBC and RBC drives speculative interest and validates the value of the litigation-linked CVRs.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Disciplined financial management, reducing operating cash burn by 60% YoY in Q1 2026 and securing a runway through July 2027.
Innovative, first-in-class mechanism of action for lead candidate Lucid-MS, targeting demyelination in multiple sclerosis rather than simple immune suppression.
Non-dilutive revenue potential from a 19.84% stake and a 7% royalty agreement with Unbuzzd Wellness Inc. on the unbuzzd™ beverage.
Asymmetric upside potential from a $700 million market manipulation lawsuit against major Canadian banks, which recently cleared a major motion to dismiss.

Key Investment Risks

Regulatory delays due to the active FDA clinical hold on the Lucid-MS Phase 2 Investigational New Drug (IND) application.
High historical stock price volatility and a transition to a shareholders' deficit in Q1 2026 due to warrant and derivative liabilities.
Commercialization risk associated with Unbuzzd Wellness Inc.'s ability to successfully launch and scale a new functional beverage category.
Early-stage clinical risk, as Lucid-MS has only completed Phase 1 safety trials and has yet to prove efficacy in human patients.

Thesis Invalidation Triggers

Failure to resolve the FDA clinical hold on Lucid-MS within the next 12 months.
A significant increase in quarterly cash burn above $2.5 million, rapidly depleting the treasury runway before clinical milestones are met.
Bankruptcy or failure of Unbuzzd Wellness Inc. to secure funding or launch its nationwide commercialization campaign.
An adverse ruling or dismissal of the $700 million market manipulation lawsuit.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.